DE69925571D1 - Sulphonamid-derivate zur behandlung von störungen des zentralnervensystems - Google Patents
Sulphonamid-derivate zur behandlung von störungen des zentralnervensystemsInfo
- Publication number
- DE69925571D1 DE69925571D1 DE69925571T DE69925571T DE69925571D1 DE 69925571 D1 DE69925571 D1 DE 69925571D1 DE 69925571 T DE69925571 T DE 69925571T DE 69925571 T DE69925571 T DE 69925571T DE 69925571 D1 DE69925571 D1 DE 69925571D1
- Authority
- DE
- Germany
- Prior art keywords
- nervous system
- central nervous
- treating disorders
- sulphonamide derivatives
- sulphonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9801392 | 1998-01-22 | ||
GBGB9801392.3A GB9801392D0 (en) | 1998-01-22 | 1998-01-22 | Novel compounds |
PCT/EP1999/000262 WO1999037623A2 (en) | 1998-01-22 | 1999-01-13 | Sulphonamide derivatives for treatment of cns disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69925571D1 true DE69925571D1 (de) | 2005-07-07 |
DE69925571T2 DE69925571T2 (de) | 2006-05-04 |
Family
ID=10825728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69925571T Expired - Fee Related DE69925571T2 (de) | 1998-01-22 | 1999-01-13 | Sulphonamid-derivate zur behandlung von störungen des zentralnervensystems |
Country Status (8)
Country | Link |
---|---|
US (1) | US6548504B1 (de) |
EP (1) | EP1049679B1 (de) |
JP (1) | JP2002501055A (de) |
CA (1) | CA2317740A1 (de) |
DE (1) | DE69925571T2 (de) |
ES (1) | ES2243044T3 (de) |
GB (1) | GB9801392D0 (de) |
WO (1) | WO1999037623A2 (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9818916D0 (en) * | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
GB9818914D0 (en) * | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
US6586592B2 (en) | 2000-06-20 | 2003-07-01 | Pharmacia & Upjohn Company | Bis-arylsulfones |
PE20020063A1 (es) | 2000-06-20 | 2002-01-30 | Upjohn Co | Bis-arilsulfonas como ligandos del receptor de 5-ht |
US7071220B2 (en) | 2000-09-18 | 2006-07-04 | Toa Eiyo Ltd. | N-substituted benzothiophenesulfonamide derivatives |
CA2422807C (en) * | 2000-09-18 | 2009-12-08 | Toa Eiyo Ltd. | N-substituted benzothiophenesulfonamide derivatives |
NZ528450A (en) | 2001-05-11 | 2006-02-24 | Biovitrum Ab | Novel, arylsulfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders |
US7718650B2 (en) | 2001-05-11 | 2010-05-18 | Biovitrum Ab | Aryl sulfonamide compounds for treating obesity |
EA008476B1 (ru) | 2001-06-11 | 2007-06-29 | Биовитрум Аб | Замещенные сульфонамиды, способ их получения и их применение в качестве лечебного средства для лечения расстройств цнс, ожирения и диабета типа ii |
JP2005526724A (ja) * | 2002-02-13 | 2005-09-08 | グラクソ グループ リミテッド | 抗精神病剤としてのベンゼンスルホンアミド誘導体 |
EP1495004A2 (de) * | 2002-02-13 | 2005-01-12 | Glaxo Group Limited | Benzensulfonamidderivate und deren verwendung als dopamin d2 und d3 rezeptor liganden |
DE60304695T2 (de) * | 2002-02-13 | 2006-09-21 | Glaxo Group Ltd., Greenford | 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo[d]azepin-derivate mit 5-hat-6-rezeptor affinität zur behandlung von erkrankungen des zentralnervensystems |
EP1476428B1 (de) * | 2002-02-22 | 2010-11-17 | Pharmacia & Upjohn Company LLC | Pyridylsulfon-derivate als 5-ht6 rezeptor liganden |
JP4455064B2 (ja) * | 2002-03-27 | 2010-04-21 | グラクソ グループ リミテッド | キノリン誘導体および5−ht6リガンドとしてのその使用 |
UA76877C2 (uk) | 2002-05-13 | 2006-09-15 | Ф.Хоффманн-Ля Рош Аг | Похідні бензоксазину як 5-нт6 модулятори і їх застосування |
EP1897881A3 (de) | 2002-06-20 | 2009-03-18 | Biovitrum AB (publ) | Zur Behandlung von Obesitas, Typ II-Diabetes und ZNS-Erkrankungen geeignete Verbindungen |
JP4754821B2 (ja) | 2002-06-20 | 2011-08-24 | プロキシマゲン・リミテッド | 肥満症、ii型糖尿病およびcns障害の治療に有用な新規化合物 |
ES2274285T3 (es) * | 2002-10-18 | 2007-05-16 | F. Hoffmann-La Roche Ag | 4-piperanzinilbencenosulfonilindoles con afinidad al receptor 5-ht6. |
GB0305575D0 (en) | 2003-03-11 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
ATE313532T1 (de) | 2003-07-22 | 2006-01-15 | Arena Pharm Inc | Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen |
SE0303480D0 (sv) | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
EP1676841A1 (de) * | 2004-12-30 | 2006-07-05 | Esteve Laboratorios Dr. Esteve S.A. | Substituierte Indazolsulfonamid- und 2,3-Dihydroindolyl-Sulfonamidverbindungen, deren Herstellung und Verwendung in Medikamenten |
NZ566495A (en) | 2005-08-12 | 2010-06-25 | Suven Life Sciences Ltd | Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands |
KR101250820B1 (ko) | 2005-08-16 | 2013-04-04 | 수벤 라이프 사이언시스 리미티드 | 개선된 로사르탄 제조 방법 |
WO2008084492A1 (en) | 2007-01-08 | 2008-07-17 | Suven Life Sciences Limited | 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands |
US20100041672A1 (en) * | 2007-03-21 | 2010-02-18 | Glaxo Group Limited | Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome |
MX2009011461A (es) | 2007-05-03 | 2009-11-10 | Suven Life Sciences Ltd | Compuestos de aminoalcoxiarilsulfonamida y su uso como ligandos de la 5-hidroxitriptamina6. |
CA2703157C (en) | 2007-10-26 | 2013-02-05 | Suven Life Sciences Limited | Amino arylsulfonamide compounds and their use as 5-ht6 ligands |
WO2009074607A1 (en) | 2007-12-12 | 2009-06-18 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
EP2103596A1 (de) | 2008-03-18 | 2009-09-23 | Laboratorios Del. Dr. Esteve, S.A. | Verfahren zur Herstellung von N-(Phenylethyl)-Anilinsalzen und deren Solvate zur nützlichen Verwendung als Serotonin-5-HT6-Antagonisten |
WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
WO2010032257A1 (en) | 2008-09-17 | 2010-03-25 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands |
EA019496B1 (ru) | 2008-09-17 | 2014-04-30 | Сувен Лайф Сайенсиз Лимитед | Арилсульфонамидные аминосоединения и их применение в качестве лигандов 5-ht |
WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
KR101463190B1 (ko) | 2010-01-05 | 2014-11-18 | 수벤 라이프 사이언시스 리미티드 | 5ht6 수용체 리간드인 술폰 화합물 |
WO2015090233A1 (en) | 2013-12-20 | 2015-06-25 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
CN105085436B (zh) | 2014-04-19 | 2019-08-16 | 广东东阳光药业有限公司 | 磺酰胺类衍生物及其在药物上的应用 |
WO2016201373A1 (en) | 2015-06-12 | 2016-12-15 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder |
CN108472285A (zh) | 2015-07-15 | 2018-08-31 | 阿速万科学有限责任公司 | 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE620236R (fr) * | 1961-07-14 | 1963-01-14 | May & Baker Ltd | Nouvelles pipérazines N-N disubstituées |
US3647790A (en) | 1969-04-08 | 1972-03-07 | American Home Prod | Ouinoxalinyl-oxazolidines and -oxazines |
US4532240A (en) * | 1982-09-09 | 1985-07-30 | Warner-Lambert Company | Diaminopyrimidines |
DE3411993A1 (de) | 1984-03-31 | 1985-10-10 | Bayer Ag, 5090 Leverkusen | Substituierte benzopyrane, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimittel |
GB8609630D0 (en) * | 1986-04-19 | 1986-05-21 | Pfizer Ltd | Anti-arrhythmia agents |
CA2144669A1 (en) * | 1994-03-29 | 1995-09-30 | Kozo Akasaka | Biphenyl derivatives |
ATE231846T1 (de) * | 1996-05-29 | 2003-02-15 | Warner Lambert Co | Benzoxazinone als dopamine -d4- rezeptor- antagonisten |
US5939451A (en) | 1996-06-28 | 1999-08-17 | Hoffmann-La Roche Inc. | Use of sulfonamides |
IL133870A0 (en) * | 1997-07-11 | 2001-04-30 | Smithkline Beecham Plc | Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation |
-
1998
- 1998-01-22 GB GBGB9801392.3A patent/GB9801392D0/en not_active Ceased
-
1999
- 1999-01-13 EP EP99904792A patent/EP1049679B1/de not_active Expired - Lifetime
- 1999-01-13 JP JP2000528547A patent/JP2002501055A/ja active Pending
- 1999-01-13 CA CA002317740A patent/CA2317740A1/en not_active Abandoned
- 1999-01-13 WO PCT/EP1999/000262 patent/WO1999037623A2/en active IP Right Grant
- 1999-01-13 ES ES99904792T patent/ES2243044T3/es not_active Expired - Lifetime
- 1999-01-13 DE DE69925571T patent/DE69925571T2/de not_active Expired - Fee Related
- 1999-01-13 US US09/600,558 patent/US6548504B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2002501055A (ja) | 2002-01-15 |
EP1049679A2 (de) | 2000-11-08 |
WO1999037623A3 (en) | 1999-10-21 |
GB9801392D0 (en) | 1998-03-18 |
WO1999037623A2 (en) | 1999-07-29 |
DE69925571T2 (de) | 2006-05-04 |
ES2243044T3 (es) | 2005-11-16 |
EP1049679B1 (de) | 2005-06-01 |
CA2317740A1 (en) | 1999-07-29 |
US6548504B1 (en) | 2003-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69925571D1 (de) | Sulphonamid-derivate zur behandlung von störungen des zentralnervensystems | |
DE69936335D1 (de) | Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen | |
DE69922914D1 (de) | Stimulationssystem zur Behandlung von Erkrankungen bezüglich des Magenspeiseröhrenreflux | |
DE69910368D1 (de) | Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen | |
ATE224189T1 (de) | Antikonvulsive sulfamatderivate zur behandlung von fettleibigkeit | |
DE69737402D1 (de) | Vorrichtung zur Behandlung von neurodegenerativen Störungen | |
DE60019556D1 (de) | 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit | |
DE69918222D1 (de) | Intranasale Zubereitungen zur Behandlung sexueller Störungen | |
ATE310566T1 (de) | 5ht2-agoniste zur behandlung des glaukoms | |
DE69934877D1 (de) | Biochanin-angereicherter extrakt zur behandlung von estrogenabhängigen erkrankungen | |
DE69936890D1 (de) | Vorrichtung zur Behandlung von Ischämie | |
DE69736862D1 (de) | System zur genetischen behandlung von stoerungen der herzleistung | |
ATE269303T1 (de) | Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen | |
DE60019555D1 (de) | 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit | |
ID27214A (id) | Triazolopiridina untuk pengobatan gangguan trombosis | |
DE60104791D1 (de) | Cyclobutendion-Derivate zur Behandlung von Artherosclerose | |
DE69905214D1 (de) | Mittel zur Behandlung der Osteoporose | |
DE69735417D1 (de) | 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen | |
EE200000391A (et) | Triasiiniühendid kesknärvisüsteemihäirete raviks | |
ATE230741T1 (de) | 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen | |
ATE287718T1 (de) | Benzenesulfonamide derivate in kombination mit beta-blockern zur behandlung von störungen des autonomen nervensystems | |
DE60130691D1 (de) | Indolderivate zur Behandlung von Erkrankungen des Zentralnervensystems | |
DE60117122D1 (de) | Verwendung von mirtazapin zur behandlung von schlafstörungen | |
ATE256126T1 (de) | 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen | |
NO20010390D0 (no) | Behandling av angstsykdommer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |